SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted…
KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseases KT-621 is…
Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and OP-3136, Olema’s KAT6…
RAMAT GAN, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company…
MALVERN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused…
- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or…
Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine MetabolismCALGARY, Alberta, Oct.…
LONDON, Oct. 9, 2024 /PRNewswire/ -- BioCorteX, a leading biotech innovator, today formally announced a breakthrough in the field of Antibody-Drug…
SINGAPORE, Oct. 9, 2024 /PRNewswire/ -- AWAK Technologies, a pioneer in innovative kidney care is excited to announce its rebranding…
SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage…